Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

ASK Pharm Announces $51 Million Deal for China Rights to Iron Deficiency Product

publication date: Jan 10, 2020

Nanjing's ASK Pharm (Beijing Aosaikang Pharmaceutical) announced a $51 million agreement for greater China rights to a treatment for iron deficiency from Shield Therapeutics of the UK. Shield's Feraccru/Accrufer is a non-salt oral therapy with a novel absorption mechanism that was as effective as a standard IV treatment for the condition. ASK paid $11 million upfront for the China rights and will make up to $40 million in milestone payments, plus royalties. It will be responsible for all China development and will have manufacturing rights to the product. More details....

Stock Symbols: (SHZ: 002755) (LSE: STX)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.